AJP - Heart Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 284: H204-H214, 2003. First published September 19, 2002; doi:10.1152/ajpheart.00068.2002
0363-6135/03 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
284/1/H204    most recent
00068.2002v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rubio, R.
Right arrow Articles by Ceballos, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rubio, R.
Right arrow Articles by Ceballos, G.
Vol. 284, Issue 1, H204-H214, January 2003

Sole activation of three luminal adenosine receptor subtypes in different parts of coronary vasculature

Rafael Rubio1 and Guillermo Ceballos2

1 Departamento de Fisiologia, Faculdad de Medicina de la Universidad Autonoma de San Luis Potosi; and 2 Posgrado de la Escuela Superior de Medicina del Instituto Politecnico Nacional, San Luis Potosi ZP 78210, Mexico

In isolated guinea pig hearts saline perfused at constant flow, adenosine A1, A2A, and A3 (Ax) agonists covalently bound to a large polymer (Pol; 2,000 kDa) were intracoronarily administered, and three effects were studied: dromotropic, vascular and inotropic. The rank order of potencies were the following: dromotropic (Pol-A2APol-A1>Pol-A3) and vascular and inotropic (Pol-A2A>= Pol-A1Pol-A3), where the rank order of potency for Pol-Ax depends on the part of the coronary vascular network involved; i.e., there is a vascular heterogeneity. The large size of Pol-Ax prevents extravascular diffusion and causes it to act solely in the endothelial luminal surface. This implies their cardiac effects are due to endothelial mediators. Inhibition of nitric oxide (NO) and prostaglandin (PG) synthesis with NG-nitro-L-arginine methyl ester and indomethacin, respectively, show that the three cardiac effects of Pol-A1 were mediated by NO and PG, whereas for Pol-A2A and Pol-A3 the mediator was mainly NO but not PG. These results suggest that if Pol-Ax activated the corresponding endothelial Ax-receptor subtype, a different mediator would be produced.

luminal endothelial receptors; endothelial control; endothelial mediators; endothelial heterogeneity; parenchymal function modulation; cardiac function control


This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. P. Headrick, B. Hack, and K. J. Ashton
Acute adenosinergic cardioprotection in ischemic-reperfused hearts
Am J Physiol Heart Circ Physiol, November 1, 2003; 285(5): H1797 - H1818.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online